Xoma (XOMA) Gets a Buy Rating from Wedbush

By Austin Angelo

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Xoma (XOMAResearch Report), with a price target of $29.00. The company’s shares closed last Tuesday at $23.85.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -5.8% and a 39.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.

Currently, the analyst consensus on Xoma is a Moderate Buy with an average price target of $29.50, implying a 22.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $28.86 and a one-year low of $12.69. Currently, Xoma has an average volume of 52.42K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.